We would love to hear your thoughts about our site and services, please take our survey here.
No, CanSEEK is identical to pre|CISION. All Point's existing clinical programmes ue another FAP tech from Bachovchin that binds as you describe, but CanSEEK cleaves, as we know. How this is an improvement for radioligands I have no idea, but I guess one day we will find out.
Love it when a new one turns up. although sadly we still seem to be getting the lower grade of basher, the share price over the past 4 months tells him all he needs to know .... must try harder if you are to make a dent here laddie.
Every single indicator that you could pick is pointing North at the moment. A complete response at this early stage ? Who knows, but it would not be inconsistent with the data we have already seen. Avacta are clearly upping the ante, they are by nature cautious, so 100% things are going on under the water line. Personally, I don't think we have many more weeks to wait until some news breaks.
There is very little in the City of Hope story that could not also be said about Avacta's platform actually. The only difference is that they are boosting it at a very early stage and Avacta are not.
Why do you think the lead scientist on the project is boosting it now ? Could it be to do with raising finance for the LLP who have the licence, and in whom they have a significant stake ? Surely not.
At the AGM it was said that they did not have the evidence to categorically say that the effects were down to the drug. The patients may have had slowly progressing tumours for example. More patients are needed in the 1b to confirm that it is the action of 6K that is responsible. Drug trials take time, and they have to grind out the data to the point where no doubts remain, just the way it is.
I see no sign that HCI are in any hurry whatsoever to sell this round. I think they sold some last week enough to cover the interest payment, and they are hanging onto the rest. Today's price represents long term support, why sell when there is a potential major upside. So far as they are concerned, so what if they have to wait a while. The only FUD left now is about the timeline to crystalisation (good luck with predicting that), and the need for further fund raising (another 10% dilution shock horror) in advance of some form of deal.
It was explained at the AGM that those still on drug cannot have their situation regarded as a direct consequence of the treatment. The numbers are too low to constitute proof of any kind. Obviously Avacta and everyone else hopes that causation will be proven, but it is much too soon to run up the bunting. As has been said many many times before - patience is needed above all things.
3996 a much bigger prospect than 6K. Once the precision mechanism is accepted as working (not long to go) the the risk becomes does the analogue of Velcade do what it is supposed to, and the chances of that must be very good indeed. I would expect proper industry analysts to put a very substantial market size estimate onto it once it has passed stage 1 trials, may be 2 to 3 years from now. In the meantime, 6K will do the heavy lifting valuation wise, as it could easily be rated at a $5bn pa market potential once the finishing line is in sight. This will be a first in class FAP activated prodrug, and Avacta have exclusive access to the IP for the mechanism that underlies all future examples, of which there could be many.
Avacta are in a great spot for sure. A new target, a new method, and it is a platform not a one off. The level of innovation here perhaps explains the hesitancy on the part of the big pharma firms, and also Avacta's cautious and methodical approach to date. The tipping point approaches now though.
Think you will find that it is the frequency of the repetitive and boring posts that is by far the most irritating thing about them, yours included. Say your piece, then clear off is the best policy rather than endlessly trying to have the last word.